Wenzhan Yang
Wenzhan Yang has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Aixiang Xue
AstraZeneca, Anim Sci & Technol, Clin Pharmacol & Safety Sci, Biopharmaceut R&D, Waltham, MA USA
2 shared publicationsDipal Patel
Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Inc., Princeton, NJ 08543, USA
2 shared publicationsPhenil J. Patel
Small Molecule Design and Development, Eli Lilly and Company, Indianapolis, IN 46285, USA
2 shared publicationsSteve Cook
Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, USA
2 shared publicationsAdriana E. Tron
Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA
1 shared publicationAjay K. Nooka
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA
1 shared publication
Latest Publications
- 18 October 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (1) , 424-433
Evaluation of the impact of the polymer end groups and molecular weight on in vitro and in vivo performances of PLGA based in situ forming implants for ketoprofen
- 18 October 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (1) , 424-433
Evaluation of the impact of the polymer end groups and molecular weight on in vitro and in vivo performances of PLGA based in situ forming implants for ketoprofen
- 26 December 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 29 (2) , 103865
Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges
- 26 December 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 29 (2) , 103865
Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges
- 24 June 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 28 (9) , 103685
Current screening, design, and delivery approaches to address low permeability of chemically synthesized modalities in drug discovery and early clinical development
- 24 June 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 28 (9) , 103685
Current screening, design, and delivery approaches to address low permeability of chemically synthesized modalities in drug discovery and early clinical development
- 3 April 2023
- Published by Springer Nature in Pharmaceutical Research
- Vol. 40 (4) , 977-988
Pre-clinical Formulation Development of an in situ Meglumine Salt of AZD5991: A Novel Macrocyclic Mcl-1 Inhibitor
Purpose AZD5991 is a potent and selective macrocyclic inhibitor of Mcl-1 in clinical development. Developing an intravenous solution formulation for AZD5991 proved to be challenging primarily due to the poor intrinsic solubility of AZD5991. In this article are described studies performed to select a suitable crystalline form and to assess physicochemical properties of AZD5991 to aid in the design of a solution formulation for preclinical studies. Methods It is preferable that the preclinical formulation has a line of sight for clinical formulation. For AZD5991, a concentration of at least 20 mg/ml was required for toxicology studies. Toward this goal, extensive pre-formulation characterization of AZD5991 including solid form analysis, pH-solubility profiling and solubility determination in cosolvents and other solubilizing media were carried out. Results & discussion Crystalline Form A, which is more stable in aqueous solution and possesses acceptable thermal stability, was selected for preclinical and clinical development of AZD5991. Extensive solubility evaluation revealed an interesting pH-solubility profile that significantly enhances solubilization at pH > 8.5 to allow solution concentrations of at least 30 mg/ml by in situ meglumine salt formation. Conclusion Developing pre-clinical formulations to support in vivo studies requires a good understanding of the physicochemical properties of the drug candidates. Candidates with challenging pharmaceutic properties like the novel macrocycle molecule AZD5991, demand extensive characterization in its polymorph landscape, solubility profile and suitability evaluation of the excipients. Meglumine, a pH-adjusting and solubilizing agent, was found to be the best choice for formulating AZD5991 into an intravenous product to support preclinical studies. Graphical Abstract
- 3 April 2023
- Published by Springer Nature in Pharmaceutical Research
- Vol. 40 (4) , 977-988
Pre-clinical Formulation Development of an in situ Meglumine Salt of AZD5991: A Novel Macrocyclic Mcl-1 Inhibitor
Purpose AZD5991 is a potent and selective macrocyclic inhibitor of Mcl-1 in clinical development. Developing an intravenous solution formulation for AZD5991 proved to be challenging primarily due to the poor intrinsic solubility of AZD5991. In this article are described studies performed to select a suitable crystalline form and to assess physicochemical properties of AZD5991 to aid in the design of a solution formulation for preclinical studies. Methods It is preferable that the preclinical formulation has a line of sight for clinical formulation. For AZD5991, a concentration of at least 20 mg/ml was required for toxicology studies. Toward this goal, extensive pre-formulation characterization of AZD5991 including solid form analysis, pH-solubility profiling and solubility determination in cosolvents and other solubilizing media were carried out. Results & discussion Crystalline Form A, which is more stable in aqueous solution and possesses acceptable thermal stability, was selected for preclinical and clinical development of AZD5991. Extensive solubility evaluation revealed an interesting pH-solubility profile that significantly enhances solubilization at pH > 8.5 to allow solution concentrations of at least 30 mg/ml by in situ meglumine salt formation. Conclusion Developing pre-clinical formulations to support in vivo studies requires a good understanding of the physicochemical properties of the drug candidates. Candidates with challenging pharmaceutic properties like the novel macrocycle molecule AZD5991, demand extensive characterization in its polymorph landscape, solubility profile and suitability evaluation of the excipients. Meglumine, a pH-adjusting and solubilizing agent, was found to be the best choice for formulating AZD5991 into an intravenous product to support preclinical studies. Graphical Abstract
- Open Access
- 1 October 2022
- Published by Paradigm Academic Press Limited in Journal of Innovations in Medical Research
- Vol. 1 (3) , 38-41
Theoretical Study on the Treatment of Non-Small Cell Lung Cancer by Invigorating Spleen and Invigorating Lung and Tongfu Organs
Through the review of relevant literature, theory and practice, consultation with the teacher. To explore the mechanism of invigorating spleen, invigorating lung and tongfu in the treatment of non-small cell lung cancer after postoperative radiotherapy and chemotherapy. The method of invigorating spleen, invigorating lung and tongfu organs is actually a dialectical combination of the theory of “cultivating earth and producing gold” and the theory of “using the six organs as a whole”, which has considerable curative effect. The method of invigorating spleen, invigorating lung and tongfu can improve the overall internal environment of the body, improve the quality of life and prolong the survival period for patients with non-small cell lung cancer after postoperative radiotherapy and chemotherapy.
- 1 October 2022
- Published by Paradigm Academic Press Limited in Journal of Innovations in Medical Research
- Vol. 1 (3) , 38-41
Open AccessTheoretical Study on the Treatment of Non-Small Cell Lung Cancer by Invigorating Spleen and Invigorating Lung and Tongfu Organs
Through the review of relevant literature, theory and practice, consultation with the teacher. To explore the mechanism of invigorating spleen, invigorating lung and tongfu in the treatment of non-small cell lung cancer after postoperative radiotherapy and chemotherapy. The method of invigorating spleen, invigorating lung and tongfu organs is actually a dialectical combination of the theory of “cultivating earth and producing gold” and the theory of “using the six organs as a whole”, which has considerable curative effect. The method of invigorating spleen, invigorating lung and tongfu can improve the overall internal environment of the body, improve the quality of life and prolong the survival period for patients with non-small cell lung cancer after postoperative radiotherapy and chemotherapy.
- 11 October 2021
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 26 (10) , 1079-1089
Experimental design, development and evaluation of extended release subcutaneous thermo-responsive in situ gels for small molecules in drug discovery
The objective of this work is to develop extended release subcutaneous thermo-responsive in situ gel forming delivery systems using the following commercially available triblock polymers: poly (lactic-co-glycolic acid)-poly (ethylene glycol)-poly (lactic-co-glycolic acid) (PLGA-PEG-PLGA, copolymer A & B) and poly (lactide-co-caprolactone)-poly (ethylene glycol)-poly (lactide-co-caprolactone) (PLCL-PEG-PLCL, copolymer C). Performance of two optimized formulations containing ketoprofen as a model compound, was assessed by comparing in vitro drug release profiles with in vivo performance following subcutaneous administration in rats. This work employs a Design of Experiment (DoE) approach to explore first, the relationship between copolymer composition, concentration, and gelation temperature (GT), and second, to identify the optimal copolymer composition and drug loading in the thermo-responsive formulation. Furthermore, this work discusses the disconnect observed between in vitro drug release and in vivo pharmacokinetic (PK) profiles. In vitro, both formulations showed extended-release profiles for 5-9 days while PK parameters and plasma profiles were similar in vivo without extended release observed. In conclusion, a clear disconnection is observed between in vitro ketoprofen drug release and in vivo performance from the two thermogel formulations tested. This finding highlights a remaining challenge for thermogel formulation development, i.e., being able to accurately predict in vivo behaviour from in vitro results. Graphical Abstract
- 11 October 2021
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 26 (10) , 1079-1089
Experimental design, development and evaluation of extended release subcutaneous thermo-responsive in situ gels for small molecules in drug discovery
The objective of this work is to develop extended release subcutaneous thermo-responsive in situ gel forming delivery systems using the following commercially available triblock polymers: poly (lactic-co-glycolic acid)-poly (ethylene glycol)-poly (lactic-co-glycolic acid) (PLGA-PEG-PLGA, copolymer A & B) and poly (lactide-co-caprolactone)-poly (ethylene glycol)-poly (lactide-co-caprolactone) (PLCL-PEG-PLCL, copolymer C). Performance of two optimized formulations containing ketoprofen as a model compound, was assessed by comparing in vitro drug release profiles with in vivo performance following subcutaneous administration in rats. This work employs a Design of Experiment (DoE) approach to explore first, the relationship between copolymer composition, concentration, and gelation temperature (GT), and second, to identify the optimal copolymer composition and drug loading in the thermo-responsive formulation. Furthermore, this work discusses the disconnect observed between in vitro drug release and in vivo pharmacokinetic (PK) profiles. In vitro, both formulations showed extended-release profiles for 5-9 days while PK parameters and plasma profiles were similar in vivo without extended release observed. In conclusion, a clear disconnection is observed between in vitro ketoprofen drug release and in vivo performance from the two thermogel formulations tested. This finding highlights a remaining challenge for thermogel formulation development, i.e., being able to accurately predict in vivo behaviour from in vitro results. Graphical Abstract
- 1 March 2021
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (3) , 713-723
Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development
- 1 March 2021
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (3) , 713-723
Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development
- 3 January 2020
- Published by Springer Nature in The AAPS Journal
- Vol. 22 (2) , 21
The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules
The druggability and developability space is rapidly evolving in the post-genomic era. In the past, Lipinski’s rule-of-five (Ro5) emerged and served as a guide for drug-like molecule design for oral...
- 3 January 2020
- Published by Springer Nature in The AAPS Journal
- Vol. 22 (2) , 21
The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules
The druggability and developability space is rapidly evolving in the post-genomic era. In the past, Lipinski’s rule-of-five (Ro5) emerged and served as a guide for drug-like molecule design for oral...
- Top Cited PapersOpen Access
- 17 December 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-14
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and resistance to anticancer therapies highlighting the potential of Mcl-1 inhibitors as anticancer drugs. Here, we describe AZD5991, a rationally designed macrocyclic molecule with high selectivity and affinity for Mcl-1 currently in clinical development. Our studies demonstrate that AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells, most notably myeloma and acute myeloid leukemia, by activating the Bak-dependent mitochondrial apoptotic pathway. AZD5991 shows potent antitumor activity in vivo with complete tumor regression in several models of multiple myeloma and acute myeloid leukemia after a single tolerated dose as monotherapy or in combination with bortezomib or venetoclax. Based on these promising data, a Phase I clinical trial has been launched for evaluation of AZD5991 in patients with hematological malignancies (NCT03218683).
- 17 December 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-14
Top Cited PapersOpen AccessDiscovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and resistance to anticancer therapies highlighting the potential of Mcl-1 inhibitors as anticancer drugs. Here, we describe AZD5991, a rationally designed macrocyclic molecule with high selectivity and affinity for Mcl-1 currently in clinical development. Our studies demonstrate that AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells, most notably myeloma and acute myeloid leukemia, by activating the Bak-dependent mitochondrial apoptotic pathway. AZD5991 shows potent antitumor activity in vivo with complete tumor regression in several models of multiple myeloma and acute myeloid leukemia after a single tolerated dose as monotherapy or in combination with bortezomib or venetoclax. Based on these promising data, a Phase I clinical trial has been launched for evaluation of AZD5991 in patients with hematological malignancies (NCT03218683).
- 31 August 2006
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 64 (1) , 9-15
A novel method to prepare highly encapsulated interferon-α-2b containing liposomes for intramuscular sustained release
- 31 August 2006
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 64 (1) , 9-15
A novel method to prepare highly encapsulated interferon-α-2b containing liposomes for intramuscular sustained release